Early intradetrusor injection of Onabotulinumtoxin A in patients with subacute spinal cord injury: The SCIBOT study
DOI:
https://doi.org/10.2340/sju.v61.46428Keywords:
Spinal cord injury, neurogenic lower urinary tract dysfunction, onabotulinumtoxin A, spinal shock phase, patient reported outcome measuresAbstract
Objectives: The aim of this study was to examine if early intradetrusor injections of onabotulinumtoxin A (BTX) permanently prevent the development of neurogenic detrusor overactivity (NDO) in patients with spinal cord injury (SCI).
Materials and methods: Double-blinded randomised controlled trial. Patients with a sensorimotor complete subacute traumatic suprasacral SCI received intradetrusor injection of BTX or placebo at baseline (within 12 weeks after injury) and 3 months later. Urodynamic and clinical evaluation was performed at baseline, at 3 months, at 12 months and at long-term follow-up after >24 months. The primary endpoint was occurrence of NDO with contractions above 40 cmH2O. The secondary endpoints included comparisons of urodynamic parameters, as well as clean intermittent catheterisation (CIC) frequency, occurrence of urinary incontinence, and quality of life (QOL) evaluated by questionnaires.
Results: Nine patients were included, with four in the placebo group and five patients in the BTX group. Two patients in the placebo group but none in the BTX group developed NDO with contractions above 40 cmH2O. Regarding the secondary outcome variables, there were lower maximum detrusor pressure, less frequent CIC, less incontinence, and better QOL in the BTX group at >24 months follow up. Although there was a trend toward better outcome measures, none of the differences were statistically significant. No adverse events were related to BTX in either group.
Conclusion: Intradetrusor injection of BTX in patients with SCI during the subacute phase seems to be safe and may be beneficial, but further studies are needed.
Downloads
References
BickenbachJ, Biering-Sørensen F, Knott J, et al. A global picture of spinal cord injury. In: J Bickenbach, editor. International perspectives on spinal cord injury. Geneva, Switzerland World Health Organization; 2013. Chap 2, p. 14.
Anderson CE, Birkhäuser V, Jordan X, et al. Urological management at discharge from acute spinal cord injury rehabilitation: a descriptive analysis from a population-based prospective cohort. Eur Urol Open Sci. 2022;38:1–9. DOI: https://doi.org/10.1016/j.euros.2022.01.005
Galloway NT, Mekras JA, Helms M, et al. An objective score to predict upper tract deterioration in myelodysplasia. J Urol. 1991; 145(3):535–537. DOI: https://doi.org/10.1016/S0022-5347(17)38389-1
McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981; 126(2):205–209. DOI: https://doi.org/10.1016/S0022-5347(17)54449-3
Tarcan T, Sekerci CA, Akbal C, et al. Is 40 cm H2O detrusor leak point pressure cut-off reliable for upper urinary tract protection in children with myelodysplasia? Neurourol Urodyn. 2017;36(3):759–763. DOI: https://doi.org/10.1002/nau.23017
Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21(10):1371–1383. DOI: https://doi.org/10.1089/neu.2004.21.1371
de Groat WC, Yoshimura N. Plasticity in reflex pathways to the lower urinary tract following spinal cord injury. Exp Neurol. 2012;235(1): 123–132. DOI: https://doi.org/10.1016/j.expneurol.2011.05.003
Oliveira R, Coelho A, Franquinho F, et al. Effects of early intravesical administration of resiniferatoxin to spinal cord-injured rats in neurogenic detrusor overactivity. Neurourol Urodyn. 2019;38(6):1540–1550. DOI: https://doi.org/10.1002/nau.24032
Thomas C, Kim JH, Torimoto K, et al. Early capsaicin intervention for neurogenic bladder in a rat model of spinal cord injury. Biomed Res. 2007;28(5):255–259. DOI: https://doi.org/10.2220/biomedres.28.255
Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–750. DOI: https://doi.org/10.1016/j.eururo.2011.07.002
Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Research Support, Non-U.S. Gov’t. Eur Urol. 2012;62(6):1157–1164. DOI: https://doi.org/10.1016/j.eururo.2012.03.031
Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol. 2010;57(5):884–890. DOI: https://doi.org/10.1016/j.eururo.2009.12.022
Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977–982; discussion 982–983. DOI: https://doi.org/10.1097/01.ju.0000169481.42259.54
Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700–706. DOI: https://doi.org/10.1016/j.eururo.2008.04.037
Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175(6):2341–2344. DOI: https://doi.org/10.1016/S0022-5347(06)00258-8
Bushnell JY, Cates LN, Hyde JE, et al. Early detrusor application of botulinum toxin A results in reduced bladder hypertrophy and fibrosis after spinal cord injury in a rodent model. Toxins (Basel). 2022;14(11):777. DOI: https://doi.org/10.3390/toxins14110777
Rosier P, Schaefer W, Lose G, et al. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243–1260. DOI: https://doi.org/10.1002/nau.23124
Barry MJ, Fowler FJ, Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–1557; discussion 1564. DOI: https://doi.org/10.1016/S0022-5347(17)36966-5
Badia X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials. Comparative Study Research Support, Non-U.S. Gov’t. Eur Urol. 1997;31(2):129–140. DOI: https://doi.org/10.1159/000474438
Best KL, Ethans K, Craven BC, et al. Identifying and classifying quality of life tools for neurogenic bladder function after spinal cord injury: a systematic review. J Spinal Cord Med. 2017;40(5):505–529. DOI: https://doi.org/10.1080/10790268.2016.1226700
Lundqvist C, Siosteen A, Sullivan L, et al. Spinal cord injuries: a shortened measure of function and mood. Clinical Trial Research Support, Non-U.S. Gov’t. Spinal Cord. 1997;35(1):17–21. DOI: https://doi.org/10.1038/sj.sc.3100347
Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000;55(4):490–494. DOI: https://doi.org/10.1016/S0090-4295(99)00553-1
Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010;67(1):74–84. DOI: https://doi.org/10.1002/ana.21814
Elmelund M, Klarskov N, Bagi P, et al. Renal deterioration after spinal cord injury is associated with length of detrusor contractions during cystometry – a study with a median of 41 years follow-up. Neurourol Urodyn. 2017;36(6):1607–1615. DOI: https://doi.org/10.1002/nau.23163
Farrelly E, Lindbo L, Seiger A. The Stockholm Spinal Cord Uro Study: 3. Urodynamic characteristics in a regional prevalence group of persons with spinal cord injury and indications for improved follow-up. Scand J Urol. 2021;55(5):412–418. DOI: https://doi.org/10.1080/21681805.2021.1954994
Temeltas G, Tikiz C, Dagci T, et al. The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: is there any difference between early and late application? J Urol. 2005;174(6):2393–2396. DOI: https://doi.org/10.1097/01.ju.0000180410.78774.b5
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ole Jacob Nilsen, Thomas Glott, Henriette Veiby Holm, Célia Duarte Cruz, Lars Frich
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
